相似文献
1
Antibody-based HIV-1 vaccines: recent developments and future directions.
PLoS Med. 2007 Dec;4(12):e348. doi: 10.1371/journal.pmed.0040348.
2
Fc receptor but not complement binding is important in antibody protection against HIV.
Nature. 2007 Sep 6;449(7158):101-4. doi: 10.1038/nature06106.
3
HIV/AIDS: allied responses.
Nature. 2007 Sep 6;449(7158):29-30. doi: 10.1038/449029a.
4
Tailored immunogens for rationally designed antibody-based HIV-1 vaccines.
Trends Immunol. 2015 Aug;36(8):437-9. doi: 10.1016/j.it.2015.07.001. Epub 2015 Jul 11.
5
Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.
Springer Semin Immunopathol. 1997;18(3):371-90. doi: 10.1007/BF00813504.
6
Serum antibody directed against synthetic peptides derived from HIV-1 protein sequence obtained from 26 Japanese HIV-1-infected individuals.
AIDS. 1991 Sep;5(9):1140-1. doi: 10.1097/00002030-199109000-00015.
7
Serological responses to candidate AIDS vaccines.
AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S145-8.
8
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
J Virol. 2018 Feb 12;92(5). doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.
9
[Development of a vaccine against HIV: is this aim accomplishable?].
MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:36-9.
10
New insights into protective humoral responses and HIV vaccines.
AIDS. 2001;15 Suppl 5:S105-15. doi: 10.1097/00002030-200100005-00014.
引用本文的文献
1
2
Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.
Vaccines (Basel). 2022 Mar 2;10(3):384. doi: 10.3390/vaccines10030384.
3
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development.
Curr HIV/AIDS Rep. 2022 Feb;19(1):86-93. doi: 10.1007/s11904-021-00597-4. Epub 2022 Jan 28.
4
What Has 30 Years of HIV Vaccine Research Taught Us?
Vaccines (Basel). 2013 Oct 30;1(4):513-26. doi: 10.3390/vaccines1040513.
5
Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).
Ther Adv Vaccines. 2013 Jul;1(2):67-80. doi: 10.1177/2051013613494534.
6
Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.
PLoS One. 2014 Feb 14;9(2):e88735. doi: 10.1371/journal.pone.0088735. eCollection 2014.
7
Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.
PLoS Pathog. 2013;9(9):e1003639. doi: 10.1371/journal.ppat.1003639. Epub 2013 Sep 26.
8
BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.
Blood. 2013 Dec 12;122(25):4013-20. doi: 10.1182/blood-2013-06-506949. Epub 2013 Sep 10.
9
Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaques.
PLoS One. 2013 Aug 14;8(8):e70814. doi: 10.1371/journal.pone.0070814. eCollection 2013.
10
Organizing the HIV vaccine development effort.
Curr Opin HIV AIDS. 2013 Sep;8(5):369-75. doi: 10.1097/COH.0b013e328363f5b6.
本文引用的文献
1
Fc receptor but not complement binding is important in antibody protection against HIV.
Nature. 2007 Sep 6;449(7158):101-4. doi: 10.1038/nature06106.
2
Broad HIV-1 neutralization mediated by CD4-binding site antibodies.
Nat Med. 2007 Sep;13(9):1032-4. doi: 10.1038/nm1624. Epub 2007 Aug 26.
3
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10193-8. doi: 10.1073/pnas.0608635104. Epub 2007 May 31.
4
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.
PLoS Pathog. 2007 May 4;3(5):e63. doi: 10.1371/journal.ppat.0030063.
5
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
J Virol. 2007 Jun;81(12):6548-62. doi: 10.1128/JVI.02749-06. Epub 2007 Apr 4.
6
The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
J Immunol. 2007 Apr 1;178(7):4424-35. doi: 10.4049/jimmunol.178.7.4424.
7
Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Virology. 2007 Jun 20;363(1):79-90. doi: 10.1016/j.virol.2007.01.015. Epub 2007 Feb 15.
8
Structural definition of a conserved neutralization epitope on HIV-1 gp120.
Nature. 2007 Feb 15;445(7129):732-7. doi: 10.1038/nature05580.
9
Rational modifications of HIV-1 envelope glycoproteins for immunogen design.
Curr Pharm Des. 2007;13(2):213-27. doi: 10.2174/138161207779313632.
10
Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage.
Protein Eng Des Sel. 2007 Feb;20(2):81-90. doi: 10.1093/protein/gzl057. Epub 2007 Jan 22.
Zotero 插件